RxDoctor Payments Data

Michael Floyd, MD

Internal Medicine · Maryville, TNNPI 1861470809

Payments from drug & device makers

$2,181in general payments, 2019–2025

Across 100 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$335
  • Pfizer$277
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$257
  • AstraZeneca$206
  • Laborie Medical Technologies Corp.$194
  • Merck$184
  • plus $728 from 13 others

What the payments were for

  • Food & beverage$2,09096%
  • Education$914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,181 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$106,110
Medicare patients
463
Services billed
1,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban383$60,779
NuedextaDextromethorphan Hbr/Quinidine75$38,465
GemtesaVibegron246$29,927
CreonLipase/Protease/Amylase27$27,354
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$18,002
XareltoRivaroxaban117$16,689
Levothyroxine Sodium1,392$15,563
LinzessLinaclotide26$14,955
NamzaricMemantine Hcl/Donepezil Hcl53$7,870
Lantus SolostarInsulin Glargine,hum.Rec.Anlog92$7,406
Spiriva HandihalerTiotropium Bromide12$6,540
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,968
Divalproex Sodium120$5,957
Divalproex Sodium ErDivalproex Sodium12$5,768
Allopurinol254$4,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$277$60,779383 claims
AbbVieCreon, Linzess, Namzaric$335$50,179106 claims
Johnson & JohnsonXarelto$89$16,689117 claims
Boehringer IngelheimJardiance$21$4,47628 claims
MerckJanuvia$184$4,34531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Maryville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →